Metronomic Doxorubicin Plus Low-Dose Radiation in Preclinical Breast Cancer

This preclinical study explores whether metronomic doxorubicin scheduling combined with low-dose gamma radiation could inform lower-toxicity breast cancer strategies, though its findings remain experimental.

doxorubicinanthracyclinemetronomic chemotherapylow-dose radiationgamma radiationbreast cancerpreclinical studyradiotherapy Oncology Pharmacy

Background Information

Metronomic doxorubicin plus low-dose radiation shows promise for breast cancer.

Breast cancer is a leading cause of cancer-related deaths in females, and optimizing treatment regimens to minimize side effects is crucial. The study found that metronomic doxorubicin (DOX) with low-dose gamma radiation enhanced apoptosis and reduced tumor size in an animal model. These findings suggest potential for decreased side effects and improved outcomes with this combined regimen, though further clinical trials are necessary. Combining metronomic doxorubicin with low-dose radiation may offer effective breast cancer treatment with fewer side effects.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Abdelrahman IY, Saif-Elnasr M, Attia ZR, Abd El Azeem RA, Khalifa E, Askar MA

Citation: Abdelrahman IY, Saif-Elnasr M, Attia ZR, et al. Therapeutic Efficacy of Metronomic Doxorubicin and Low Dose of Gamma Radiation on Breast Cancer Model. Cell biochemistry and function. 2026;44(8):e70278. doi:10.1002/cbf.70278

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →